Clinical Development of COVID-19 Therapeutics
$1,516,140N01FY2025AINIH
Aligos Therapeutics, Inc., South San Francisco CA
Investigators
Abstract
To support the advanced development of a candidate therapeutic. The supported research and development activities will progress the therapeutic product development and may include lead optimization, candidate selection, preclinical and IND enabling studies, Chemistry, Manufacturing, and Controls (CMC), IND submission, clinical safety and efficacy assessment. Efforts include a Phase I clinical trial.
View original record on NIH RePORTER →